Abstract
AIM:To determine the association between the use of incretin agents (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists) for the treatment of type 2 diabetes mellitus (T2DM) and the risk of any, acute and chronic, pancreatitis.RESEARCH AND DESIGN METHODS:A population-based cohort study was conducted using data from the UK Clinical
... read more